Pfizer Settles Suit Tied To Children's ADHD Medication

Benzinga

Pfizer and Tris Pharma agreed to a $41.5 million settlement with Texas over claims they manipulated quality-control testing for children’s ADHD drug Quillivant XR to keep it Medicaid-eligible. Pfizer denied wrongdoing and said its review found no safety impact, while Tris did not comment. The case stemmed from a whistleblower complaint by a former Tris technology chief.

Transcript

00:00It's Benzinga bringing Wall Street to Main Street.

00:02Pfizer and Therese Farber reached a $41.5 million settlement in Texas to resolve claims they

00:07defrauded the state's Medicaid program by manipulating quality control for an ADHD

00:11medicine for children, and according to Reuters, Texas Attorney General Ken Paxton said the

00:17settlement ends a 2023 lawsuit alleging Pfizer and Therese manipulated equivalent RXR testing

00:23from 2012 to 2018 to keep the medicine compliant and eligible for sale. Pfizer denied wrongdoing

00:28and said its review found no safety impact, while Therese did not comment. The lawsuit

00:33began with a whistleblower complaint from a former Therese technology chief.

00:36For all things money, visit Benzinga.com.

Category

Transcript

Comments

Recommended